NovoCure Ltd (NASDAQ: NVCR) kicked off on Tuesday, up 1.34% from the previous trading day, before settling in for the closing price of $17.96. Over the past 52 weeks, NVCR has traded in a range of $14.17-$34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.60% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -4.67%. With a float of $99.01 million, this company’s outstanding shares have now reached $111.48 million.
In an organization with 1488 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.16%, operating margin of -26.84%, and the pretax margin is -20.88%.
NovoCure Ltd (NVCR) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of NovoCure Ltd is 11.19%, while institutional ownership is 84.12%. The most recent insider transaction that took place on May 03 ’25, was worth 10,604. In this transaction Chief Operating Officer of this company sold 592 shares at a rate of $17.91, taking the stock ownership to the 83,556 shares. Before that another transaction happened on May 05 ’25, when Company’s Officer proposed sale 592 for $17.91, making the entire transaction worth $10,604.
NovoCure Ltd (NVCR) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -4.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.26% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
Take a look at NovoCure Ltd’s (NVCR) current performance indicators. Last quarter, stock had a quick ratio of 1.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Let’s dig in a bit further. During the last 5-days, its volume was 0.85 million. That was inferior than the volume of 0.91 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.88%. Additionally, its Average True Range was 0.91.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 19.66%, which indicates a significant decrease from 75.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.98% in the past 14 days, which was higher than the 54.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.89, while its 200-day Moving Average is $20.26. However, in the short run, NovoCure Ltd’s stock first resistance to watch stands at $18.43. Second resistance stands at $18.66. The third major resistance level sits at $19.03. If the price goes on to break the first support level at $17.84, it is likely to go to the next support level at $17.47. Assuming the price breaks the second support level, the third support level stands at $17.24.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
The company with the Market Capitalisation of 2.03 billion has total of 111,486K Shares Outstanding. Its annual sales at the moment are 605,220 K in contrast with the sum of -168,630 K annual income. Company’s last quarter sales were recorded 154,990 K and last quarter income was -34,320 K.
